Home » Newsletters » BioWorld Science

BioWorld Science

March 19, 2020

View Archived Issues

NEFAs nefarious role in pancreatitis

Enrollment begins in phase I study of AmnioBoost for treatment of COVID-19

Opioid analgesic CYX-6 displays antinociception without constipation, respiratory depression

Cellenkos seeks to advance CK-0802 for CoV-ARDS

CanSino receives clearance in China for phase I trials with Ad5-nCoV candidate vaccine for COVID-19

SELLAS presents positive data from phase II VADIS study of nelipepimut-S

Mateon to develop OT-101 against COVID-19

Positive final data from phase Ib study of Allocetra-OTS in severe sepsis

Pneumagen announces new program to target COVID-19 infections

Armata awarded up to USD 5 million from CFF for the development AP-PA02

The University of Washington discloses new ERN1/ERN2 inhibitors

Clinical data published on vincristine and irinotecan in children with Wilms tumor

IDO-1 inhibitors discovered at Bristol-Myers Squibb

Testing, testing: first repurposing trial for COVID-19 falls flat

Phase II data reported for preoperative letrozole in DCIS

Zolgensma approved in Japan for SMA

Global phase III trial to evaluate Actemra for severe COVID-19 pneumonia

Researchers identify novel biomarkers in Crohn's disease

Pfizer reports phase III data on 20-valent pneumococcal conjugate vaccine in vaccine-naive adults

Cellphire cleared to begin phase II study of Thrombosomes in bleeding patients with thrombocytopenia

Northwestern University synthesizes new glucosylceramidase modulators

Xenon Pharmaceuticals patents Nav1.6 channel blockers

New antitubercular compounds identified at Monash University

Identification and optimization of isoxazole amides as potent and selective SMYD3 inhibitors

Popular Stories

Today's news in brief
BioWorld
SCAN is core circuit affected in Parkinson’s disease
BioWorld Science
Parkinson’s disease (PD) is a neurodegenerative disorder that affects movement, and tremor is one of its signatures. But it is a much more wide-ranging disorder,...
TL1A is overexpressed in hidradenitis suppurativa
BioWorld Science
Despite the availability of advanced therapeutic options, about 40%-50% of patients with hidradenitis suppurativa do not achieve significant improvement in...
Astellas’ ASP-2246 shows promise in stroke management
BioWorld Science
Astellas Pharma Inc. recently presented data regarding ASP-2246, a drug candidate comprised of an mRNA encoding the transcription factor NeuroD1 encapsulated in...
News in brief
BioWorld Asia
BioWorld Asia briefs for Feb. 10, 2026